Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer
Ontology highlight
ABSTRACT: The purpose of this study is to evaluate the safety and immunogenicity of a CEA DNA immunisation approach in patients with colorectal cancer. The DNA plasmid, tetwtCEA, encodes wild type human CEA fused to a tetanus toxoid T helper epitope. The vaccine will be delivered using an intradermal electroporation device, Derma Vax (Cyto Pulse Sciences). The following will be assessed:
* The efficiency of priming immunological responses to CEA by intradermal administration of CEA DNA in combination with electroporation.
* The efficiency of boosting immunological responses to CEA by intradermal administration of CEA DNA in combination with electroporation in subjects already vaccinated with CEA DNA.
* GM-CSF will be administered to half of the subjects primed with CEA DNA in combination with electroporation and any possible adjuvant effects of GM-CSF will be evaluated.
DISEASE(S): Colorectal Carcinoma,Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2084602 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA